The registry aims to collect and analyse information on the antineoplastic treatment of patients with metastatic esophageal, gastric or gastroesophageal junction cancer, treated in palliative intention in daily routine practice in Germany.

SAPHIR is a national, observational, prospective, longitudinal, multicenter cohort study (tumor registry platform) with the purpose to record information on the antineoplastic treatment of metastatic esophageal, gastric or gastroesophageal junction Cancer in Germany. The registry will follow patients for up to two years. It will identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented.

Health-related quality of life (HRQoL) will be evaluated for up to two years.

Inclusion Criteria:

• Histologically proven stage IV (metastatic) ESCC, EAC, GAC or GEJAC

• Planned palliative systemic first-line therapy

• Age >= 18 years

• Signed informed consent (IC)

  • Patients answering questionnaires: IC before first therapy cycle
  • Patients not answering questionnaires: IC latest 4 weeks after start of first therapy cycle

Exclusion Criteria:

• No systemic therapy for ESCC, EAC, GAC or GEJAC

Adult patients with metastatic (stage IV) esophageal squamous cell carcinoma (ESCC), esophageal adenocarcinoma (EAC), gastric adenocarcinoma (GAC) or gastroesophageal junction adenocarcinoma (GEJAC), requiring palliative systemic first-line therapy.